Pre-made Ligelizumab benchmark antibody ( Whole mAb, anti-IGHE/IgE therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-312

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-312 Category Tag

Product Details

Pre-Made Ligelizumab biosimilar, Whole Mab: Anti-IGHE/IgE therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Ligelizumab (INN; development code QGE031) is a humanized IgG1 monoclonal antibody designed for the treatment of severe asthma and chronic spontaneous urticaria. It is an anti-IgE that binds to IGHE an acts as an immunomodulator.

Products Name (INN Index)

Pre-Made Ligelizumab biosimilar, Whole Mab: Anti-IGHE/IgE therapeutic antibody

INN Name

Ligelizumab

Target

IGHE

Format

Whole mAb

Derivation

Humanized

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Phase-III

Est. Status

Active

100% SI Structure

6uqr:AC

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2012

Companies

Novartis,Tanox

Conditions Approved

NA

Conditions Active

Urticaria,Allergic asthma,Atopic dermatitis,Bullous pemphigoid

Conditions Discontinued

Hypersensitivity

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

IGHE

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide